Isolation of circulating tumor cells from glioblastoma patients by direct immunomagnetic targeting

David Lynch; Branka Powter; Joseph William Po; Adam Cooper; Celine Garrett; Eng-Siew Koh; Mark Sheridan; James van Gelder; Balsam Darwish; Simon Mckechnie; Renata Bazina; Matthias Jaeger; Tara Laurine Roberts; Paul de Souza; Therese Maria Becker

doi:10.3390/app10093338

Isolation of circulating tumor cells from glioblastoma patients by direct immunomagnetic targeting

David Lynch
, Branka Powter
, Joseph William Po
, Adam Cooper
, Celine Garrett
, Eng-Siew Koh
, Mark Sheridan
, James van Gelder
, Balsam Darwish
, Simon Mckechnie
, Renata Bazina
, Matthias Jaeger
, Tara Laurine Roberts
, Paul de Souza
, Therese Maria Becker

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Abstract

Glioblastoma (GBM) is the most common form of primary brain cancer in adults and tissue biopsies for diagnostic purposes are often inaccessible. The postulated idea that brain cancer cells cannot pass the blood-brain barrier to form circulating tumor cells (CTCs) has recently been overthrown and CTCs have been detected in the blood of GBM patients albeit in low numbers. Given the potential of CTCs to be analyzed for GBM biomarkers that may guide therapy decisions it is important to define methods to better isolate these cells. Here, we determined markers for immunomagnetic targeting and isolation of GBM-CTCs and confirmed their utility for CTC isolation from GBM patient blood samples. Further, we identified a new marker to distinguish isolated GBM-CTCs from residual lymphocytes.

Original language	English
Article number	3338
Number of pages	11
Journal	Applied Sciences
Volume	10
Issue number	9
DOIs	https://doi.org/10.3390/app10093338
Publication status	Published - 1 May 2020

Bibliographical note

Publisher Copyright:
© 2020 by the authors.

Open Access - Access Right Statement

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

biomarkers in disease
blood
cancer
circulating tumour cells
glioblastoma

Access to Document

10.3390/app10093338

Cite this

Lynch, D., Powter, B., Po, J. W., Cooper, A., Garrett, C., Koh, E.-S., Sheridan, M., van Gelder, J., Darwish, B., Mckechnie, S., Bazina, R., Jaeger, M., Roberts, T. L., Souza, P. D., & Becker, T. M. (2020). Isolation of circulating tumor cells from glioblastoma patients by direct immunomagnetic targeting. Applied Sciences, 10(9), Article 3338. https://doi.org/10.3390/app10093338

@article{f54849b5cc13422486abf219db65f601,

title = "Isolation of circulating tumor cells from glioblastoma patients by direct immunomagnetic targeting",

abstract = "Glioblastoma (GBM) is the most common form of primary brain cancer in adults and tissue biopsies for diagnostic purposes are often inaccessible. The postulated idea that brain cancer cells cannot pass the blood-brain barrier to form circulating tumor cells (CTCs) has recently been overthrown and CTCs have been detected in the blood of GBM patients albeit in low numbers. Given the potential of CTCs to be analyzed for GBM biomarkers that may guide therapy decisions it is important to define methods to better isolate these cells. Here, we determined markers for immunomagnetic targeting and isolation of GBM-CTCs and confirmed their utility for CTC isolation from GBM patient blood samples. Further, we identified a new marker to distinguish isolated GBM-CTCs from residual lymphocytes.",

keywords = "biomarkers in disease, blood, cancer, circulating tumour cells, glioblastoma",

author = "David Lynch and Branka Powter and Po, \{Joseph William\} and Adam Cooper and Celine Garrett and Eng-Siew Koh and Mark Sheridan and \{van Gelder\}, James and Balsam Darwish and Simon Mckechnie and Renata Bazina and Matthias Jaeger and Roberts, \{Tara Laurine\} and Souza, \{Paul de\} and Becker, \{Therese Maria\}",

note = "Publisher Copyright: {\textcopyright} 2020 by the authors.",

year = "2020",

month = may,

day = "1",

doi = "10.3390/app10093338",

language = "English",

volume = "10",

journal = "Applied Sciences",

issn = "2076-3417",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "9",

}

TY - JOUR

T1 - Isolation of circulating tumor cells from glioblastoma patients by direct immunomagnetic targeting

AU - Lynch, David

AU - Powter, Branka

AU - Po, Joseph William

AU - Cooper, Adam

AU - Garrett, Celine

AU - Koh, Eng-Siew

AU - Sheridan, Mark

AU - van Gelder, James

AU - Darwish, Balsam

AU - Mckechnie, Simon

AU - Bazina, Renata

AU - Jaeger, Matthias

AU - Roberts, Tara Laurine

AU - Souza, Paul de

AU - Becker, Therese Maria

PY - 2020/5/1

Y1 - 2020/5/1

N2 - Glioblastoma (GBM) is the most common form of primary brain cancer in adults and tissue biopsies for diagnostic purposes are often inaccessible. The postulated idea that brain cancer cells cannot pass the blood-brain barrier to form circulating tumor cells (CTCs) has recently been overthrown and CTCs have been detected in the blood of GBM patients albeit in low numbers. Given the potential of CTCs to be analyzed for GBM biomarkers that may guide therapy decisions it is important to define methods to better isolate these cells. Here, we determined markers for immunomagnetic targeting and isolation of GBM-CTCs and confirmed their utility for CTC isolation from GBM patient blood samples. Further, we identified a new marker to distinguish isolated GBM-CTCs from residual lymphocytes.

AB - Glioblastoma (GBM) is the most common form of primary brain cancer in adults and tissue biopsies for diagnostic purposes are often inaccessible. The postulated idea that brain cancer cells cannot pass the blood-brain barrier to form circulating tumor cells (CTCs) has recently been overthrown and CTCs have been detected in the blood of GBM patients albeit in low numbers. Given the potential of CTCs to be analyzed for GBM biomarkers that may guide therapy decisions it is important to define methods to better isolate these cells. Here, we determined markers for immunomagnetic targeting and isolation of GBM-CTCs and confirmed their utility for CTC isolation from GBM patient blood samples. Further, we identified a new marker to distinguish isolated GBM-CTCs from residual lymphocytes.

KW - biomarkers in disease

KW - blood

KW - cancer

KW - circulating tumour cells

KW - glioblastoma

UR - http://hdl.handle.net/1959.7/uws:56196

U2 - 10.3390/app10093338

DO - 10.3390/app10093338

M3 - Article

SN - 2076-3417

VL - 10

JO - Applied Sciences

JF - Applied Sciences

IS - 9

M1 - 3338

ER -

Isolation of circulating tumor cells from glioblastoma patients by direct immunomagnetic targeting

Abstract

Bibliographical note

Open Access - Access Right Statement

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this